Table 1.
Characteristics of Patients With Early Stage Higher Risk CLL Treated With Single-Agent Extended Dosing Rituximab
| Parameter | Median (range) |
|---|---|
| Age, y | 66 (44–82) |
| Median months from diagnosis (range) | 25 (1–219) |
| Hematological | |
| WBC × 109/L | 40 (9.2–181) |
| Hemoglobin (g/dL) | 13 (10–16)a |
| Platelet × 109/L | 160 (116–321) |
| Beta-2 microglobulin (mg/dL) | 3 (2–12.8) |
| No. (%) | |
|---|---|
| Sex | |
| Male | 18 (53) |
| ECOG performance status | |
| 0 | 8 (24) |
| 1 | 26 (76) |
| Rai stage | |
| 0 | 7 (21) |
| I | 15 (44) |
| II | 12 (27) |
CLL indicates chronic lymphocytic leukemia; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell count; IgH, immunoglobulin heavy.
a
Anemia in 1 patient was attributed to concomitant rheumatologic disorder; note that study antedated standardized IgH somatic mutation or ZAP-70 assays.